NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML

References

• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Eng J Med 2015; 373:1136-52; PMID:26376137; https://doi.org/10.1056/NEJMra1406184
   PubMed Web of Science ®Google Scholar
• Poste G. Bring on the biomarkers. Nature 2011; 469:156-7; PMID:21228852; https://doi.org/10.1038/469156a
   PubMed Web of Science ®Google Scholar
• Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points–the challenge of statistical validation. Nat Rev Clin Oncol 2010; 7:309-17; PMID:20368727; https://doi.org/10.1038/nrclinonc.2010.43
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92:2322-33; PMID:9746770
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH, Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1312-20; PMID:11520776; https://doi.org/10.1182/blood.V98.5.1312
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453-74; PMID:19880497; https://doi.org/10.1182/blood-2009-07-235358
   PubMed Web of Science ®Google Scholar
• Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A, Ligges S, Sauer T, Tschanter P, Thoennissen GB et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2013; 50:5768; PMID:24366930; doi:10.1200/JCO.2013.50.5768
   PubMed Web of Science ®Google Scholar
• Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301:2349-61; PMID:19509382; https://doi.org/10.1001/jama.2009.813
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016; 127:62-70; PMID:26660427; https://doi.org/10.1182/blood-2015-07-604546
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK, National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354-65; PMID:20385793; https://doi.org/10.1182/blood-2009-11-254441
   PubMed Web of Science ®Google Scholar
• Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Eng J Med 2012; 366:1079-89; PMID:22417203; https://doi.org/10.1056/NEJMoa1112304
   PubMed Web of Science ®Google Scholar
• Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 2012; 26:2019-26; PMID:22446501; https://doi.org/10.1038/leu.2012.87
   PubMed Web of Science ®Google Scholar
• Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24:1997-2005; PMID:16648500; https://doi.org/10.1200/JCO.2005.03.9594
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; https://doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016; 44:698-711; PMID:26982367; https://doi.org/10.1016/j.immuni.2016.02.025
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; https://doi.org/10.1200/JCO.2010.30.5425
   PubMed Web of Science ®Google Scholar
• Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett 2005; 100:7-13; PMID:16109445; https://doi.org/10.1016/j.imlet.2005.07.004
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9; PMID:21212348; https://doi.org/10.1126/science.1198687
   PubMed Web of Science ®Google Scholar
• Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12:239-52; PMID:22437937; https://doi.org/10.1038/nri3174
   PubMed Web of Science ®Google Scholar
• Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116:2411-9; PMID:20581313; https://doi.org/10.1182/blood-2010-05-283051
   PubMed Web of Science ®Google Scholar
• Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007; 109:323-30; PMID:16940427; https://doi.org/10.1182/blood-2005-08-027979
   PubMed Web of Science ®Google Scholar
• Garcia-Iglesias T, del Toro-Arreola A, Albarran-Somoza B, del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Dueà ± as MG, Balderas-Peña LM, Bravo-Cuellar A, Ortiz-Lazareno PC, Daneri-Navarro A. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 2009; 9:186; PMID:19531227; https://doi.org/10.1186/1471-2407-9-186
   PubMed Web of Science ®Google Scholar
• Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, Walz J, Moretta A, Olive D. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget 2015; 6:14360-73; PMID:25961317; https://doi.org/10.18632/oncotarget.3965
   PubMed Web of Science ®Google Scholar
• Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 2003; 3:108-22; PMID:12563295; https://doi.org/10.1038/nri999
   PubMed Web of Science ®Google Scholar
• Triplett BM, Horwitz EM, Iyengar R, Turner V, Holladay MS, Gan K, Behm FG, Leung W. Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia 2009; 23:1278-87; PMID:19212329; https://doi.org/10.1038/leu.2009.21
   PubMed Web of Science ®Google Scholar
• Fauriat C, Marcenaro E, Sivori S, Rey J, Gastaut JA, Moretta A, Olive D, Costello RT. Natural killer cell-triggering receptors in patients with acute leukaemia. Leuk Lymphoma 2003; 44:1683-9; PMID:14692519; https://doi.org/10.1080/1042819031000104006
   PubMed Web of Science ®Google Scholar
• Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Euro J Immunol 1999; 29:1656-66; https://doi.org/10.1002/(SICI)1521-4141(199905)29:05<1656::AID-IMMU1656>3.0.CO;2-1
   PubMed Web of Science ®Google Scholar
• Martner A, Rydström A, Riise RE, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB. Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. Oncoimmunology 2016; 5:e1041701; PMID:26942055; https://doi.org/10.1080/2162402X.2015.1041701
   PubMed Web of Science ®Google Scholar
• Clave E, Lisini D, Douay C, Giorgiani G, Busson M, Zecca M, Charron D, Bernardo ME, Toubert A, Locatelli F. A low thymic function is associated with leukemia relapse in children given T-cell-depleted HLA-haploidentical stem cell transplantation. Leukemia 2012; 26:1886-8; PMID:22430571; https://doi.org/10.1038/leu.2012.59
   PubMed Web of Science ®Google Scholar
• Forcina A, Noviello M, Carbone M, Bonini C, Bondanza A. Predicting the clinical outcome of allogeneic hematopoietic stem cell transplantation: the long and winding road toward validated immune biomarkers. Front Immunol 2013; 4:71; PMID:23531639; https://doi.org/10.3389/fimmu.2013.00071
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Barrett AJ, Schaffer M, Hagglund H, Ljungman P, Ringden O, Remberger M. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant 2009; 15:1108-15; PMID:19660724; https://doi.org/10.1016/j.bbmt.2009.05.015
   PubMed Web of Science ®Google Scholar
• Savani B, Mielke S, Adams S, Uribe M, Rezvani K, Yong A, Zeilah J, Kurlander R, Srinivasan R, Childs R et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007; 21:2145-52; PMID:17673900; https://doi.org/10.1038/sj.leu.2404892
   PubMed Web of Science ®Google Scholar
• Sullivan EM, Jeha S, Kang G, Cheng C, Rooney B, Holladay M, Bari R, Schell S, Tuggle M, Pui CH et al. NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease. Clin Cancer Res 2014; 20:5986-94; PMID:25281696; https://doi.org/10.1158/1078-0432.CCR-14-0479
   PubMed Web of Science ®Google Scholar
• Ghadially H, Ohana M, Elboim M, Gazit R, Gur C, Nagler A, Mandelboim O. NK cell receptor NKp46 regulates graft-versus-host disease. Cell Rep 2014; 7:1809-14; PMID:24882008; https://doi.org/10.1016/j.celrep.2014.05.011
   PubMed Web of Science ®Google Scholar
• Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7; PMID:21552268; https://doi.org/10.1038/nm.2366
   PubMed Web of Science ®Google Scholar
• Venton G, Labiad Y, Colle J, Fino A, Afridi S, Torres M, Monteuil S, Loriod B, Fernandez-Nunez N, Farnault L et al. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis. Immunol Res 2016; 64:1225-36; PMID:27481509; https://doi.org/10.1007/s12026-016-8848-0
   PubMed Web of Science ®Google Scholar
• Khaznadar Z, Boissel N, Agaugue S, Henry G, Cheok M, Vignon M, Geromin D, Cayuela JM, Castaigne S, Pautas C et al. Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion. J Immunol 2015; 195(6):2580-90; PMID:26246143; doi:10.4049/jimmunol.1500262
   PubMed Web of Science ®Google Scholar
• Shemer Avni Y, Kundu K, Shemesh A, Brusilovsky M, Yossef R, Meshesha M, Solomon-Alemayehu S, Levin S, Gershoni-Yahalom O, Campbell KS et al. Expression of NKp46 splice variants in nasal lavage following respiratory viral infection: domain 1-negative isoforms predominate and manifest higher activity. Front Immunol 2017; 8:161; PMID:28261217; https://doi.org/10.3389/fimmu.2017.00161
   PubMed Web of Science ®Google Scholar
• Siewiera J, Gouilly J, Hocine H-R, Cartron G, Levy C, Al-Daccak R, Jabrane-Ferrat N. Natural cytotoxicity receptor splice variants orchestrate the distinct functions of human natural killer cell subtypes. Nat Commun 2014; 6:10183; PMID:26666685; https://doi.org/10.1038/ncomms10183
   PubMed Web of Science ®Google Scholar
• Shemesh A, Brusilovsky M, Hadad U, Teltsh O, Edri A, Rubin E, Campbell KS, Rosental B, Porgador A. Survival in acute myeloid leukemia is associated with NKp44 splice variants. Oncotarget 2016; 7:32933; PMID:27102296; doi:10.18632/oncotarget.8782
   PubMed Web of Science ®Google Scholar
• Ballman KV. Biomarker: predictive or prognostic? J Clin Oncol 2015; 63:3651; PMID:26392104; doi:10.1200/JCO.2015.63.3651
   PubMed Web of Science ®Google Scholar
• Devillier R, Gelsi-Boyer V, Murati A, Prebet T, Rey J, Etienne A, D'Incan E, Charbonnier A, Blaise D, Mozziconacci MJ et al. Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients. American journal of hematology 2015; 90:E22-E4; PMID:25219760; https://doi.org/10.1002/ajh.23850
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96:4075-83; PMID:11110676
   PubMed Web of Science ®Google Scholar
• Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014; 15:986-96; PMID:25008258; https://doi.org/10.1016/S1470-2045(14)70281-5
   PubMed Web of Science ®Google Scholar
• Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 2014; 99:836-47; PMID:24488563; https://doi.org/10.3324/haematol.2013.087536
   PubMed Web of Science ®Google Scholar